Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2016; 62(1): 102-106

SERUM LEVELS OF ENDOTHELIAL MONOCYTE ACTIVATING PEPTIDE II IN TYPE 1 DIABETES

L.A. Mogylnytska, O.E. Mogylnytska

    Khmelnitsky regional hospital
DOI: https://doi.org/10.15407/fz62.01.102


Abstract

Was investigated serum level of endothelial monocyte activating peptide II (EMAP-II) and endothelium-dependent dilatation in type 1 diabetes and possible relation between those. We found an increase serum level of EMAP-II and decrease of endothelium-dependent dilatation in type 1 diabetes. It was significant correlation between EMAP-II and HbAc1, blood glucose, total cholesterol, LDL, triglycerides and inverse correlation between EMAP-II and HDL, endotheliumdependent dilatation. The revealed change of EMAP-II serum level reflects an endothelial dysfunction in type 1 diabetes, alteration of carbohydrate and lipid metabolism could influence of this pathway.

Keywords: EMAP-II; diabetes; endothelial dysfunction.

Full text: (PDF, in Ukrainian)

References

  1. Theilade S, Lajer M, Jorsal A, Tarnow L, Parving H.H., Rossing P. Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. Diabet Med. 2012 Aug;29(8):990-4. CrossRef PubMed
    2.  
  2. Adameova A, Dhalla NS. Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev. 2014 Jan; 19(1):25-33. CrossRef PubMed
    3.  
  3. Chillarón JJ, Flores Le-Roux JA, Benaiges D, PedroBotet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014 Feb;63(2):181-7. CrossRef PubMed
    4.  
  4. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013 Aug;34(31):2436-43. CrossRef PubMed PubMedCentral
    5.  
  5. Ladeia AM, Sampaio RR, Hita MC, Adan LF. Prognostic value of endothelial dysfunction in type 1 diabetes mellitus. World J Diabetes. 2014 Oct 15;5(5):601-5. CrossRef PubMed PubMedCentral
    6.  
  6. Hurks R, Eisinger MJ, Goovaerts I, van Gaal L, Vrints C, Weyler J, Hendriks J, van Schil P, Lauwers P. Early endothelial dysfunction in young type 1 diabetics. Eur J Vasc Endovasc Surg. 2009 May;37(5):611-5. CrossRef PubMed
    7.  
  7. Eltayeb AA, Ahmad FA, Sayed DM, Osama AM. Subclinical vascular endothelial dysfunctions and myocardial changes with type 1 diabetes mellitus 106 ISSN 0201-8489 Фізіол. журн., 2016, Т. 62, № 1 in children and adolescents. Pediatr Cardiol. 2014 Aug;35(6):965-74.
    8.  
  8. Van Horssen R, Eggermont AM, ten Hagen TL. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 2006 Oct;17(5):339-48. CrossRef PubMed
    9.  
  9. Thompson JL, Ryan JA, Barr ML, Franc B, Starnes VA, Schwarz MA. Potential role for antiangiogenic proteins in the myocardial infarction repair process. J Surg Res. 2004 Jan;116(1):156-64. CrossRef PubMed
    10.  
  10. Yuan C, Yan L, Solanki P, Vatner SF, Vatner DE, Schwarz MA. Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis// J Mol Cell Cardiol. 2015 Feb;79:224-31. CrossRef PubMed PubMedCentral
    11.  
  11. Tsai BM, Wang M, Clauss M, Sun P, Meldrum DR. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R767-71. CrossRef PubMed
    12.  
  12. Kohner EM, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe. Eur J Ophthalmol. 1991 Jan-Mar; 1(1):45-54. PubMed
    13.  
  13. Mogensen CE. Diabetes mellitus and the kidney. Kidney Int. 1982 May; 21(5):673-5. CrossRef PubMed
    14.  
  14. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Noninvasive detection of endothelial dysfunction in children and adults at risk for atherosclerosis Lancet. 1992 Nov 7;340(8828):1111-5. CrossRef  
  15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. CrossRef  
  16. Eltayeb AA, Ahmad FA, Sayed DM, Osama AM. Subclinical vascular endothelial dysfunctions and myocardial changes with type 1 diabetes mellitus in children and adolescents. Pediatr Cardiol 2014; 35: 965-974. CrossRef PubMed
    17.  
  17. Martinet W, De Meyer I, Cools N, Timmerman V, Bult H, Bosmans J, De Meyer GR. Cell death-mediated cleavage of the attraction signal p43 in human atherosclerosis: implications for plaque destabilization. Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1415-22. CrossRef PubMed
    18.  
  18. Symons JD, Abel ED. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev Endocr Metab Disord. 2013 March; 14(1): 59–68. CrossRef PubMed PubMedCentral
    19.  
  19. Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest. 2009 Jan;89(1):38-46. CrossRef PubMed
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.